GLS 5300

Drug Profile

GLS 5300

Alternative Names: GLS5300; MERS DNA vaccine - Inovio; MERS vaccine - GeneOne

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer GeneOne Life Science; Inovio Pharmaceuticals; Walter Reed Army Institute of Research
  • Class Antivirals; DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Middle East respiratory syndrome coronavirus

Most Recent Events

  • 09 Nov 2017 Phase-I/II clinical trials in Middle East respiratory syndrome coronavirus (Prevention) in South Korea (Intradermal)
  • 18 Sep 2017 Inovio Pharmaceuticals plans a phase I/IIa trial for Middle east respiratory syndrome in South Korea in 2017
  • 18 Sep 2017 Immunogenicity data from a phase I trial in Middle east respiratory syndrome released by Inovio Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top